UA73986C2 - АЕРОЗОЛЬНА КОМПОЗИЦІЯ, ЩО МІСТИТЬ <font face="Symbol">b</font>2-АДРЕНЕРГІЧНИЙ АГОНІСТ ТРИВАЛОЇ ДІЇ, ДОЗУЮЧИЙ ІНГАЛЯТОР ПІД ТИСКОМ ТА СПОСІБ ЙОГО ЗАПОВНЕННЯ - Google Patents
АЕРОЗОЛЬНА КОМПОЗИЦІЯ, ЩО МІСТИТЬ <font face="Symbol">b</font>2-АДРЕНЕРГІЧНИЙ АГОНІСТ ТРИВАЛОЇ ДІЇ, ДОЗУЮЧИЙ ІНГАЛЯТОР ПІД ТИСКОМ ТА СПОСІБ ЙОГО ЗАПОВНЕННЯ Download PDFInfo
- Publication number
- UA73986C2 UA73986C2 UA2002118859A UA2002118859A UA73986C2 UA 73986 C2 UA73986 C2 UA 73986C2 UA 2002118859 A UA2002118859 A UA 2002118859A UA 2002118859 A UA2002118859 A UA 2002118859A UA 73986 C2 UA73986 C2 UA 73986C2
- Authority
- UA
- Ukraine
- Prior art keywords
- formoterol
- nea
- cylinders
- acid
- solution composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract description 15
- 239000000443 aerosol Substances 0.000 title abstract description 12
- 239000000048 adrenergic agonist Substances 0.000 title description 2
- 238000000034 method Methods 0.000 title description 2
- 230000002035 prolonged effect Effects 0.000 title 1
- 239000002253 acid Substances 0.000 abstract description 17
- 239000003380 propellant Substances 0.000 abstract description 9
- 229910052782 aluminium Inorganic materials 0.000 abstract description 8
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 abstract description 8
- 239000006184 cosolvent Substances 0.000 abstract description 8
- 150000005828 hydrofluoroalkanes Chemical class 0.000 abstract description 4
- 239000002245 particle Substances 0.000 abstract description 4
- 239000011248 coating agent Substances 0.000 abstract description 2
- 238000000576 coating method Methods 0.000 abstract description 2
- 229910001220 stainless steel Inorganic materials 0.000 abstract description 2
- 239000010935 stainless steel Substances 0.000 abstract description 2
- 239000011149 active material Substances 0.000 abstract 1
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract 1
- 239000011707 mineral Substances 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 33
- 239000000243 solution Substances 0.000 description 31
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 23
- 229960002848 formoterol Drugs 0.000 description 23
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 16
- 239000004480 active ingredient Substances 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 12
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 11
- 238000003860 storage Methods 0.000 description 11
- OBRNDARFFFHCGE-PERKLWIXSA-N (S,S)-formoterol fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 OBRNDARFFFHCGE-PERKLWIXSA-N 0.000 description 9
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 9
- 229960000193 formoterol fumarate Drugs 0.000 description 9
- 229960002052 salbutamol Drugs 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000011521 glass Substances 0.000 description 5
- 150000007524 organic acids Chemical class 0.000 description 5
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 229940126601 medicinal product Drugs 0.000 description 4
- 150000007522 mineralic acids Chemical class 0.000 description 4
- 235000005985 organic acids Nutrition 0.000 description 4
- 239000003513 alkali Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- -1 hydrochloric Chemical class 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 229960001361 ipratropium bromide Drugs 0.000 description 2
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 239000001272 nitrous oxide Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- BNPSSFBOAGDEEL-NMFAMCKASA-N 4-[(1r)-2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol;sulfuric acid Chemical compound OS(O)(=O)=O.CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-NMFAMCKASA-N 0.000 description 1
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 229950000210 beclometasone dipropionate Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- YACLQRRMGMJLJV-UHFFFAOYSA-N chloroprene Chemical compound ClC(=C)C=C YACLQRRMGMJLJV-UHFFFAOYSA-N 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000005007 epoxy-phenolic resin Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960001022 fenoterol Drugs 0.000 description 1
- 229960000289 fluticasone propionate Drugs 0.000 description 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- SYCWERNQGSKYAG-QVRIGTRMSA-N hydron;8-hydroxy-5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]-1h-quinolin-2-one;chloride Chemical compound Cl.C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2 SYCWERNQGSKYAG-QVRIGTRMSA-N 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 238000010943 off-gassing Methods 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- 229960005018 salmeterol xinafoate Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000000954 titration curve Methods 0.000 description 1
- 150000003611 tocopherol derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/124—Aerosols; Foams characterised by the propellant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2000/004635 WO2001089480A1 (en) | 2000-05-22 | 2000-05-22 | Stable pharmaceutical solution formulations for pressurised metered dose inhalers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA73986C2 true UA73986C2 (uk) | 2005-10-17 |
Family
ID=8163952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2002118859A UA73986C2 (uk) | 2000-05-22 | 2000-05-22 | АЕРОЗОЛЬНА КОМПОЗИЦІЯ, ЩО МІСТИТЬ <font face="Symbol">b</font>2-АДРЕНЕРГІЧНИЙ АГОНІСТ ТРИВАЛОЇ ДІЇ, ДОЗУЮЧИЙ ІНГАЛЯТОР ПІД ТИСКОМ ТА СПОСІБ ЙОГО ЗАПОВНЕННЯ |
Country Status (40)
Families Citing this family (110)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010031244A1 (en) * | 1997-06-13 | 2001-10-18 | Chiesi Farmaceutici S.P.A. | Pharmaceutical aerosol composition |
| DZ2947A1 (fr) * | 1998-11-25 | 2004-03-15 | Chiesi Farma Spa | Inhalateur à compteur de dose sous pression. |
| IT1303788B1 (it) * | 1998-11-25 | 2001-02-23 | Chiesi Farma Spa | Formulazioni di aerosol medicinali. |
| US6315985B1 (en) * | 1999-06-18 | 2001-11-13 | 3M Innovative Properties Company | C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability |
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| IT1313553B1 (it) | 1999-07-23 | 2002-09-09 | Chiesi Farma Spa | Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione. |
| AU1534501A (en) * | 1999-11-23 | 2001-06-04 | Glaxo Group Limited | Pharmaceutical formulations of salmeterol |
| IT1317720B1 (it) * | 2000-01-07 | 2003-07-15 | Chiesi Farma Spa | Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani. |
| IT1318514B1 (it) * | 2000-05-12 | 2003-08-27 | Chiesi Farma Spa | Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari. |
| HRP20021025B1 (hr) * | 2000-05-22 | 2013-11-22 | Chiesi Farmaceutici S.P.A. | Formulacije stabilnih farmaceutskih otopina za inhalatore s odmjerenom dozom pod tlakom |
| US20060257324A1 (en) | 2000-05-22 | 2006-11-16 | Chiesi Farmaceutici S.P.A. | Pharmaceutical solution formulations for pressurised metered dose inhalers |
| AU5858501A (en) * | 2000-05-23 | 2001-12-03 | Glaxo Group Ltd | Aerosol container for formulations of salmeterol xinafoate |
| FI20002177A0 (fi) * | 2000-10-02 | 2000-10-02 | Orion Yhtymae Oyj | Uusi yhdistelmä astman hoitoon |
| EP1241113A1 (en) | 2001-03-12 | 2002-09-18 | CHIESI FARMACEUTICI S.p.A. | Inhaler with means for improving chemical stability of medicinal aerosol solution contained therein |
| HU229798B1 (en) * | 2001-03-30 | 2014-07-28 | Jagotec Ag | Medical aerosol compositions and process for their preparation |
| US20030055026A1 (en) | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
| US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| EP1273292B1 (en) | 2001-07-02 | 2004-05-26 | CHIESI FARMACEUTICI S.p.A. | Optimised formulation of tobramycin for aerosolization |
| US7306925B2 (en) | 2001-11-09 | 2007-12-11 | Vanderbilt University | Phage antibodies to radiation-inducible neoantigens |
| US7906102B2 (en) | 2001-10-03 | 2011-03-15 | Vanderbilt University | Ligands to radiation-induced molecules |
| EP1415647A1 (en) * | 2002-10-23 | 2004-05-06 | CHIESI FARMACEUTICI S.p.A. | "Long-acting beta-2 agonists ultrafine formulations" |
| JP2005523905A (ja) * | 2002-03-01 | 2005-08-11 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | ホルモテロール（ｆｏｒｍｏｔｅｒｏｌ）超微細調合物 |
| EP1340492A1 (en) * | 2002-03-01 | 2003-09-03 | CHIESI FARMACEUTICI S.p.A. | Aerosol formulations for pulmonary administration of medicaments having systemic effects |
| WO2004022052A1 (de) * | 2002-08-14 | 2004-03-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Aerosolformulierung für die inhalation enthaltend ein anticholinergikum |
| US20040166065A1 (en) | 2002-08-14 | 2004-08-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Aerosol formulation for inhalation comprising an anticholinergic |
| DE10237739A1 (de) * | 2002-08-17 | 2004-02-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Inhalative Arzneimittel enthaltend ein neues Anticholinergikum in Kombination mit Corticosteroiden und Betamimetika |
| US7244742B2 (en) * | 2002-08-17 | 2007-07-17 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Pharmaceutical compositions for inhalation containing an anticholinergic, corticosteroid and betamimetic |
| EP1452179A1 (en) * | 2003-02-27 | 2004-09-01 | CHIESI FARMACEUTICI S.p.A. | Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid |
| US20050003024A1 (en) * | 2003-03-04 | 2005-01-06 | The Procter & Gamble Company | Regulation of mammalian hair growth |
| TWI359675B (en) | 2003-07-10 | 2012-03-11 | Dey L P | Bronchodilating β-agonist compositions |
| NZ545442A (en) * | 2003-07-29 | 2010-05-28 | Boehringer Ingelheim Int | Medicaments for inhalation comprising betamimetics and an aclidinium salt known as 3-(2-hydroxy-2,2-dithiophen-2-yl-acetoxy)-1-(3-phenoxypropyl)-l-azoniabicyclo[2.2.2]octane |
| US20050026948A1 (en) * | 2003-07-29 | 2005-02-03 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising an anticholinergic and a betamimetic |
| EP1651224B1 (en) * | 2003-07-31 | 2011-10-05 | Boehringer Ingelheim International GmbH | Medicaments for inhalation comprising an anticholinergic and a betamimetic |
| CA2534693A1 (en) * | 2003-08-05 | 2005-02-17 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising steroids and a betamimetic |
| SG146648A1 (en) * | 2003-09-15 | 2008-10-30 | Vectura Ltd | Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation |
| GB0323684D0 (en) | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
| AR041873A1 (es) * | 2003-10-30 | 2005-06-01 | Pablo Cassara Srl Lab | Una formulacion farmaceutica en aerosol adecuada para la inhalacion oral o nasal que contienen glucocorticoides en solucion estable al almacenamiento; un metodo para estabilzar formulaciones y uso de un agente estabilizante |
| EP1595531A1 (en) * | 2004-05-13 | 2005-11-16 | CHIESI FARMACEUTICI S.p.A. | Stable pharmaceutical solution formulations for pressurized metered dose inhalers |
| KR20070000476A (ko) * | 2004-02-27 | 2007-01-02 | 키에시 파르마슈티시 엣스. 피. 에이. | 압축화 계량된 도스흡입용 안정된 약제용액 제제 |
| UA88894C2 (ru) * | 2004-02-27 | 2009-12-10 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Стабильные фармацевтические композиции в виде растворов для ингаляторов с дозатором, которые находятся под давлением |
| CA2565747A1 (en) * | 2004-05-13 | 2005-12-01 | Chiesi Farmaceutici S.P.A. | Medicinal aerosol formulation products with improved chemical stability |
| ES2257152B1 (es) * | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
| GB0501956D0 (en) * | 2005-01-31 | 2005-03-09 | Arrow Internat | Nebulizer formulation |
| AU2006218177B2 (en) | 2005-02-25 | 2012-04-12 | Chiesi Farmaceutici S.P.A. | Pharmaceutical aerosol formulations for pressurized metered dose inhalers comprising a sequestering agent |
| EP1879620A2 (en) * | 2005-03-30 | 2008-01-23 | Schering Corporation | Medicaments and methods combining an anticholinergic, a corticosteroid, and a long acting beta agonist |
| DE102005055960A1 (de) * | 2005-11-24 | 2007-07-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Aerosolformulierung für die Inhalation enthaltend ein Anticholinergikum |
| GB0525680D0 (en) | 2005-12-16 | 2006-01-25 | Peplin Ltd | Therapeutic compositions |
| US20070286814A1 (en) * | 2006-06-12 | 2007-12-13 | Medispray Laboratories Pvt. Ltd. | Stable aerosol pharmaceutical formulations |
| GB0613761D0 (en) * | 2006-07-11 | 2006-08-23 | Norton Healthcare Ltd | A pharmaceutical formulation and method for the preparation thereof |
| EP1982709A1 (en) | 2007-04-19 | 2008-10-22 | CHIESI FARMACEUTICI S.p.A. | Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma |
| US8227027B2 (en) * | 2007-12-07 | 2012-07-24 | Presspart Gmbh & Co. Kg | Method for applying a polymer coating to an internal surface of a container |
| EP2077132A1 (en) | 2008-01-02 | 2009-07-08 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dispensing device, storage device and method for dispensing a formulation |
| GB0801876D0 (en) * | 2008-02-01 | 2008-03-12 | Vectura Group Plc | Suspension formulations |
| US20090208424A1 (en) * | 2008-02-19 | 2009-08-20 | Todd Maibach | Compositions and methods for delivery of solution to the skin |
| EP3311820A1 (en) * | 2008-02-26 | 2018-04-25 | Sunovion Respiratory Development Inc. | Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations |
| US20100055045A1 (en) * | 2008-02-26 | 2010-03-04 | William Gerhart | Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations |
| EP2100598A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2100599A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| AU2009308412B2 (en) * | 2008-10-23 | 2015-11-26 | Sunovion Pharmaceuticals Inc. | Arformoterol and tiotropium compositions and methods for use |
| EP2201934A1 (en) * | 2008-12-23 | 2010-06-30 | CHIESI FARMACEUTICI S.p.A. | Tiotropium aerosol formulation products with improved chemical stability |
| EP2662472B1 (de) | 2009-03-31 | 2019-02-27 | Boehringer Ingelheim International Gmbh | Verfahren zur Beschichtung einer Oberfläche eines Bauteils |
| WO2010133294A2 (de) | 2009-05-18 | 2010-11-25 | Boehringer Ingelheim International Gmbh | Adapter, inhalationseinrichtung und zerstäuber |
| RS53514B1 (en) | 2009-10-02 | 2015-02-27 | Chiesi Farmaceutici S.P.A. | PHARMACEUTICAL AEROSOL FORMOTEROL FORMULATION AND BECLOMETHASONE DIPROPIONATE |
| GB0918149D0 (en) | 2009-10-16 | 2009-12-02 | Jagotec Ag | Improved medicinal aerosol formulation |
| GB0918150D0 (en) * | 2009-10-16 | 2009-12-02 | Jagotec Ag | Improved formulations |
| EP2504051B1 (en) | 2009-11-25 | 2019-09-04 | Boehringer Ingelheim International GmbH | Nebulizer |
| MX2012005961A (es) | 2009-11-25 | 2012-06-14 | Boehringer Ingelheim Int | Nebulizador. |
| US10016568B2 (en) | 2009-11-25 | 2018-07-10 | Boehringer Ingelheim International Gmbh | Nebulizer |
| EP2512438B1 (en) | 2009-12-16 | 2017-01-25 | 3M Innovative Properties Company | Formulations and methods for controlling mdi particle size delivery |
| ES2468835T3 (es) * | 2009-12-23 | 2014-06-17 | Chiesi Farmaceutici S.P.A. | Terapia combinada para EPOC |
| UA106098C2 (uk) | 2009-12-23 | 2014-07-25 | К'Єзі Фармачеутічі С.П.А. | Аерозольна композиція для хозл |
| NZ600790A (en) * | 2009-12-23 | 2014-09-26 | Chiesi Farma Spa | Combination therapy for copd |
| US9943654B2 (en) | 2010-06-24 | 2018-04-17 | Boehringer Ingelheim International Gmbh | Nebulizer |
| WO2012010854A1 (en) | 2010-07-23 | 2012-01-26 | Cipla Limited | Inhalation formulations comprising carmoterol in combination with a corticosteroid |
| EP2694220B1 (de) | 2011-04-01 | 2020-05-06 | Boehringer Ingelheim International GmbH | Medizinisches gerät mit behälter |
| EP2510928A1 (en) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
| US9827384B2 (en) | 2011-05-23 | 2017-11-28 | Boehringer Ingelheim International Gmbh | Nebulizer |
| WO2013019730A1 (en) | 2011-07-29 | 2013-02-07 | The Washington University | Antibodies to tip-1 and grp78 |
| GB201200504D0 (en) * | 2011-12-19 | 2012-02-22 | Teva Branded Pharmaceutical Prod R & D Inc | An inhaler |
| GB201200525D0 (en) | 2011-12-19 | 2012-02-29 | Teva Branded Pharmaceutical Prod R & D Inc | An inhalable medicament |
| WO2013152894A1 (de) | 2012-04-13 | 2013-10-17 | Boehringer Ingelheim International Gmbh | Zerstäuber mit kodiermitteln |
| EP3030298B1 (en) | 2013-08-09 | 2017-10-11 | Boehringer Ingelheim International GmbH | Nebulizer |
| EP2835146B1 (en) | 2013-08-09 | 2020-09-30 | Boehringer Ingelheim International GmbH | Nebulizer |
| CA2935302C (en) * | 2013-12-30 | 2022-06-21 | Chiesi Farmaceutici S.P.A. | Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination |
| PL3089735T3 (pl) | 2013-12-30 | 2018-12-31 | Chiesi Farmaceutici S.P.A. | Trwała ciśnieniowa kompozycja roztworu aerozolowego kombinacji bromku glikopironium i formoterolu |
| EA032850B1 (ru) | 2014-05-07 | 2019-07-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Контейнер, небулайзер и способ изготовления контейнера |
| JP6745225B2 (ja) | 2014-05-07 | 2020-08-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 容器、表示デバイス、及びネブライザ |
| ES2874029T3 (es) | 2014-05-07 | 2021-11-04 | Boehringer Ingelheim Int | Nebulizador |
| US10034866B2 (en) | 2014-06-19 | 2018-07-31 | Teva Branded Pharmaceutical Products R&D, Inc. | Inhalable medicament comprising tiotropium |
| US10449261B2 (en) | 2014-07-24 | 2019-10-22 | Washington University | Compositions targeting radiation-induced molecules and methods of use thereof |
| CN104225739A (zh) * | 2014-09-30 | 2014-12-24 | 四川普锐特医药科技有限责任公司 | 一种医用定量吸入气雾剂 |
| BR122020022602B1 (pt) | 2015-12-04 | 2024-03-05 | Mexichem Fluor S.A. De C.V. | Composição farmacêutica |
| US10098837B2 (en) | 2016-07-28 | 2018-10-16 | Chiesi Farmaceutici S.P.A. | Combination therapy for COPD |
| US11352436B2 (en) | 2017-02-10 | 2022-06-07 | Washington University | Antibodies to TIP1 and methods of use thereof |
| MA52756A (fr) | 2018-06-04 | 2021-04-14 | Lupin Inc | Compositions pharmaceutiques stables pour inhalateurs doseurs sous pression |
| WO2020152548A1 (en) * | 2019-01-24 | 2020-07-30 | Glenmark Pharmaceuticals Limited | Stable aerosol inhalation compositions of formoterol |
| CN112137957B (zh) | 2019-06-26 | 2022-07-29 | 长风药业股份有限公司 | 一种药用吸入气雾剂及其制备方法 |
| US20220395454A1 (en) * | 2019-12-02 | 2022-12-15 | Chiesi Farmaceutici S.P.A. | Stainless steel can for pressurised metered dose inhalers |
| CN117599290A (zh) * | 2020-01-28 | 2024-02-27 | 奇斯药制品公司 | 包含缓冲药物制剂的加压定量吸入器 |
| GB202001537D0 (en) * | 2020-02-05 | 2020-03-18 | Consort Medical Plc | Pressurised dispensing container |
| NZ790703A (en) | 2020-02-20 | 2025-06-27 | Chiesi Farm Spa | Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation |
| US11826382B2 (en) | 2020-05-01 | 2023-11-28 | Tygrus, LLC | Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses |
| US11642372B2 (en) * | 2020-05-01 | 2023-05-09 | Tygrus, LLC | Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses |
| US12042514B2 (en) | 2020-05-01 | 2024-07-23 | Tygrus, LLC | Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses |
| JP2023540171A (ja) | 2020-07-31 | 2023-09-22 | ケモ リサーチ， エス．エル． | 吸入投与のための併用療法 |
| MX2023003754A (es) * | 2020-10-09 | 2023-04-24 | Chiesi Farm Spa | Formulacion farmaceutica para inhalador presurizado de dosis medidas. |
| GB2614901A (en) | 2022-01-21 | 2023-07-26 | Nanopharm Ltd | Inhalable formulations |
| EP4504338A1 (en) | 2022-04-06 | 2025-02-12 | RAPT Therapeutics, Inc. | Chemokine receptor modulators and uses thereof |
| WO2023227782A1 (en) | 2022-05-27 | 2023-11-30 | Chiesi Farmaceutici S.P.A. | A pharmaceutical formulation for pressurised metered dose inhaler |
| US20250302742A1 (en) | 2022-05-27 | 2025-10-02 | Chiesi Farmaceutici S.P.A. | A pharmaceutical formulation for pressurised metered dose inhaler |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3361306A (en) | 1966-03-31 | 1968-01-02 | Merck & Co Inc | Aerosol unit dispensing uniform amounts of a medically active ingredient |
| US3622053A (en) | 1969-12-10 | 1971-11-23 | Schering Corp | Aerosol inhaler with flip-up nozzle |
| MX3864E (es) | 1975-05-27 | 1981-08-26 | Syntex Corp | Un proceso para prepara el compuesto cristalino 6-fluiro-11b 21-dihiroxi-16 17-isopropilidendioxipregna-1 4-dien-3 20-diona |
| US4185100A (en) | 1976-05-13 | 1980-01-22 | Johnson & Johnson | Topical anti-inflammatory drug therapy |
| US4499108A (en) * | 1983-06-08 | 1985-02-12 | Schering Corporation | Stable pleasant-tasting albuterol sulfate pharmaceutical formulations |
| GB8334494D0 (en) * | 1983-12-24 | 1984-02-01 | Tanabe Seiyaku Co | Carbostyril derivatives |
| IT1196142B (it) | 1984-06-11 | 1988-11-10 | Sicor Spa | Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti |
| US5192528A (en) | 1985-05-22 | 1993-03-09 | Liposome Technology, Inc. | Corticosteroid inhalation treatment method |
| GB8828477D0 (en) | 1988-12-06 | 1989-01-05 | Riker Laboratories Inc | Medical aerosol formulations |
| US5225183A (en) | 1988-12-06 | 1993-07-06 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
| IL97065A (en) | 1990-02-02 | 1994-01-25 | Fisons Plc | Repellent preparations for aerosol |
| EP0563048A1 (en) | 1990-12-19 | 1993-10-06 | Smithkline Beecham Corporation | Aerosol formulations |
| US6006745A (en) | 1990-12-21 | 1999-12-28 | Minnesota Mining And Manufacturing Company | Device for delivering an aerosol |
| EP0504112A3 (en) | 1991-03-14 | 1993-04-21 | Ciba-Geigy Ag | Pharmaceutical aerosol formulations |
| US5874063A (en) * | 1991-04-11 | 1999-02-23 | Astra Aktiebolag | Pharmaceutical formulation |
| RU2114642C1 (ru) | 1991-05-21 | 1998-07-10 | Эбботт Лабораториз | Аэрозольное ингаляторное устройство |
| EP0601036B1 (de) | 1991-08-29 | 1999-04-28 | Broncho-Air Medizintechnik AG | Medizinisches gerät zur inhalation von dosier-aerosolen |
| IL103238A (en) | 1991-09-25 | 1995-07-31 | Fisons Plc | Pressurised aerosol compositions |
| IL104068A (en) | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant |
| JP3908269B2 (ja) * | 1991-12-18 | 2007-04-25 | スリーエム カンパニー | 懸濁エアゾール製剤 |
| DE4230876A1 (de) | 1992-03-17 | 1993-09-23 | Asta Medica Ag | Druckgaspackungen unter verwendung von polyoxyethylen-glyceryl-oleaten |
| AU6048694A (en) * | 1992-12-09 | 1994-07-04 | Paul D. Jager | Stabilized medicinal aerosol solution formulations |
| SE9203743D0 (sv) * | 1992-12-11 | 1992-12-11 | Astra Ab | Efficient use |
| AU4066693A (en) | 1992-12-23 | 1994-07-19 | Bernhard Hugemann | Compacted drug body for use in the mechanical generation of inhalable active-substance particles |
| JPH08507792A (ja) * | 1993-03-17 | 1996-08-20 | ミネソタ マイニング アンド マニュファクチャリング カンパニー | ジオール−二酸から誘導される分散助剤を含むエーロゾル配合物 |
| KR100321649B1 (ko) | 1993-03-17 | 2002-07-22 | 미네소타 마이닝 앤드 매뉴팩춰링 캄파니 | 에스테르,아미드또는머캅토에스테르로부터유도된분산보조제를함유하는에어로졸제제 |
| US6596260B1 (en) | 1993-08-27 | 2003-07-22 | Novartis Corporation | Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol |
| DK0735884T3 (da) | 1993-12-20 | 2000-10-09 | Minnesota Mining & Mfg | Flunisolid-aerosolformuleringer |
| GB9425160D0 (en) | 1994-12-10 | 1995-02-08 | Glaxo Group Ltd | Medicaments |
| CN1088580C (zh) * | 1994-12-22 | 2002-08-07 | 阿斯特拉公司 | 气溶胶药物制剂 |
| GB9426252D0 (en) * | 1994-12-24 | 1995-02-22 | Glaxo Group Ltd | Pharmaceutical composition |
| DE4446891A1 (de) | 1994-12-27 | 1996-07-04 | Falk Pharma Gmbh | Stabile wäßrige Budesonid-Lösung |
| US5653961A (en) | 1995-03-31 | 1997-08-05 | Minnesota Mining And Manufacturing Company | Butixocort aerosol formulations in hydrofluorocarbon propellant |
| NZ306280A (en) | 1995-04-14 | 1999-07-29 | Glaxo Wellcome Inc | Metered dose inhaler for salmeterol |
| AP960A (en) | 1995-04-14 | 2001-04-20 | Glaxo Wellcome Inc | Metered dose inhaler for fluticasone propionate. |
| GEP20002254B (en) * | 1995-04-14 | 2000-10-25 | Glaxo Wellcome Inc | Metered Dose Inhaler, the Inhaler System Comprising the Same and Method for Treatment of Respiratory Disturbances |
| AU718851B2 (en) | 1995-04-14 | 2000-04-20 | Smithkline Beecham Corporation | Metered dose inhaler for beclomethasone dipropionate |
| US6135628A (en) * | 1995-10-13 | 2000-10-24 | Boehringer Ingelheim Pharmceuticals, Inc. | Method and apparatus for homogenizing aerosol formulations |
| GB9612297D0 (en) | 1996-06-11 | 1996-08-14 | Minnesota Mining & Mfg | Medicinal aerosol formulations |
| AU3453897A (en) | 1996-07-08 | 1998-02-02 | Rhone-Poulenc Rorer Limited | Medicinal cyclosporin-a aerosol solution formulation |
| WO1998003533A1 (en) | 1996-07-24 | 1998-01-29 | Oligos Etc. And Oligos Therapeutics, Inc. | Antisense oligonucleotides as antibacterial agents |
| GB9616237D0 (en) * | 1996-08-01 | 1996-09-11 | Norton Healthcare Ltd | Aerosol formulations |
| GB9620187D0 (en) | 1996-09-27 | 1996-11-13 | Minnesota Mining & Mfg | Medicinal aerosol formulations |
| US6413496B1 (en) | 1996-12-04 | 2002-07-02 | Biogland Ireland (R&D) Limited | Pharmaceutical compositions and devices for their administration |
| ATE301991T1 (de) * | 1996-12-04 | 2005-09-15 | Link Products Ltd | Arzneimittel zusammensetzungen und vorrichtungen zu deren verabreichung |
| AU718967B2 (en) * | 1997-02-05 | 2000-05-04 | Jagotec Ag | Medical aerosol formulations |
| US6126919A (en) | 1997-02-07 | 2000-10-03 | 3M Innovative Properties Company | Biocompatible compounds for pharmaceutical drug delivery systems |
| US5891419A (en) | 1997-04-21 | 1999-04-06 | Aeropharm Technology Limited | Environmentally safe flunisolide aerosol formulations for oral inhalation |
| US6000537A (en) * | 1997-06-10 | 1999-12-14 | U.S. Philips Corporation | Housing with readable side walls for a disc-shaped information carrier |
| GB2326334A (en) | 1997-06-13 | 1998-12-23 | Chiesi Farma Spa | Pharmaceutical aerosol compositions |
| US20010031244A1 (en) | 1997-06-13 | 2001-10-18 | Chiesi Farmaceutici S.P.A. | Pharmaceutical aerosol composition |
| US6324827B1 (en) * | 1997-07-01 | 2001-12-04 | Bp Corporation North America Inc. | Method of generating power in a dry low NOx combustion system |
| BR7702049U (pt) | 1997-09-05 | 1999-09-14 | Chiesi Farma Spa | Bico pulverizador para utilização em inalador oral para medicamentos aerossóis |
| US5954047A (en) | 1997-10-17 | 1999-09-21 | Systemic Pulmonary Development, Ltd. | Methods and apparatus for delivering aerosolized medication |
| EP1075278A1 (en) * | 1998-01-13 | 2001-02-14 | AstraZeneca UK Limited | PHARMACEUTICAL COMPOSITIONS COMPRISING A COMPOUND HAVING DOPAMINE (D 2?) RECEPTOR AGONIST ACTIVITY AND A COMPOUND (B) HAVING $g(b) 2?-ADRENORECEPTOR AGONIST ACTIVITY |
| US6045784A (en) | 1998-05-07 | 2000-04-04 | The Procter & Gamble Company | Aerosol package compositions containing fluorinated hydrocarbon propellants |
| SE9802073D0 (sv) | 1998-06-11 | 1998-06-11 | Astra Ab | New use |
| RS49977B (sr) * | 1998-06-18 | 2008-09-29 | Boehringer Ingelheim Pharmaceuticals Inc., | Farmaceutske formulacije za aerosolove sa dve ili više aktivnih supstanci |
| US6451285B2 (en) | 1998-06-19 | 2002-09-17 | Baker Norton Pharmaceuticals, Inc. | Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant |
| US6241969B1 (en) | 1998-06-26 | 2001-06-05 | Elan Corporation Plc | Aqueous compositions containing corticosteroids for nasal and pulmonary delivery |
| EP1100465B1 (de) | 1998-07-24 | 2004-11-24 | Jago Research Ag | Medizinische aerosolformulierungen |
| DE59904648D1 (de) | 1998-08-04 | 2003-04-24 | Jago Res Ag Muttenz | Medizinische aerosolformulierungen |
| US6136294C1 (en) * | 1998-09-22 | 2002-09-24 | Aeropharm Technology Inc | Amino acid stabilized medical aerosol formulation |
| CZ20011362A3 (cs) * | 1998-10-17 | 2001-09-12 | Boehringer Ingelheim Pharma Kg | Skladovatelný koncentrát účinné látky s formoterolem |
| DE19847969A1 (de) | 1998-10-17 | 2000-04-20 | Boehringer Ingelheim Pharma | Lagerfähig flüssige Formulierung mit Formoterol |
| PT1283036E (pt) | 1998-11-13 | 2008-03-06 | Jagotec Ag | Inalador de pó seco de dose múltipla com um reservatório de pó |
| IT1303788B1 (it) * | 1998-11-25 | 2001-02-23 | Chiesi Farma Spa | Formulazioni di aerosol medicinali. |
| DZ2947A1 (fr) * | 1998-11-25 | 2004-03-15 | Chiesi Farma Spa | Inhalateur à compteur de dose sous pression. |
| US6290930B1 (en) | 1998-12-18 | 2001-09-18 | Baker Norton Pharmaceuticals, Inc. | Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide |
| US6004537A (en) * | 1998-12-18 | 1999-12-21 | Baker Norton Pharmaceuticals, Inc. | Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol |
| GB9902689D0 (en) * | 1999-02-08 | 1999-03-31 | Novartis Ag | Organic compounds |
| DK1158958T3 (da) | 1999-03-05 | 2007-10-08 | Chiesi Farma Spa | Forbedret pulverformulering til inhalering |
| US6315985B1 (en) | 1999-06-18 | 2001-11-13 | 3M Innovative Properties Company | C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability |
| US20030032632A1 (en) | 1999-12-24 | 2003-02-13 | Crispps Leslie Alan | Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate |
| IT1317846B1 (it) | 2000-02-22 | 2003-07-15 | Chiesi Farma Spa | Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva. |
| IT1318514B1 (it) * | 2000-05-12 | 2003-08-27 | Chiesi Farma Spa | Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari. |
| HRP20021025B1 (hr) | 2000-05-22 | 2013-11-22 | Chiesi Farmaceutici S.P.A. | Formulacije stabilnih farmaceutskih otopina za inhalatore s odmjerenom dozom pod tlakom |
| EP1340492A1 (en) * | 2002-03-01 | 2003-09-03 | CHIESI FARMACEUTICI S.p.A. | Aerosol formulations for pulmonary administration of medicaments having systemic effects |
| JP2005523905A (ja) * | 2002-03-01 | 2005-08-11 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | ホルモテロール（ｆｏｒｍｏｔｅｒｏｌ）超微細調合物 |
| EP1595531A1 (en) * | 2004-05-13 | 2005-11-16 | CHIESI FARMACEUTICI S.p.A. | Stable pharmaceutical solution formulations for pressurized metered dose inhalers |
-
2000
- 2000-05-22 HR HRP20021025AA patent/HRP20021025B1/hr not_active IP Right Cessation
- 2000-05-22 CA CA002411047A patent/CA2411047C/en not_active Expired - Lifetime
- 2000-05-22 CN CNB008195641A patent/CN1213732C/zh not_active Expired - Lifetime
- 2000-05-22 MX MXPA02011414A patent/MXPA02011414A/es active IP Right Grant
- 2000-05-22 CZ CZ20023835A patent/CZ303833B6/cs not_active IP Right Cessation
- 2000-05-22 WO PCT/EP2000/004635 patent/WO2001089480A1/en active Application Filing
- 2000-05-22 AU AU5070100A patent/AU5070100A/xx active Pending
- 2000-05-22 HU HU0302007A patent/HU230804B1/hu active Protection Beyond IP Right Term
- 2000-05-22 IL IL15295500A patent/IL152955A0/xx unknown
- 2000-05-22 UA UA2002118859A patent/UA73986C2/uk unknown
- 2000-05-22 DZ DZ003358A patent/DZ3358A1/fr active
- 2000-05-22 BR BR0015884-4A patent/BR0015884A/pt not_active IP Right Cessation
- 2000-05-22 AU AU2000250701A patent/AU2000250701B2/en not_active Expired
- 2000-05-22 ME MEP-2008-321A patent/ME00220B/me unknown
- 2000-05-22 EE EEP200200649A patent/EE05167B1/xx unknown
- 2000-05-22 JP JP2001585725A patent/JP5392880B2/ja not_active Expired - Lifetime
- 2000-05-22 SK SK1652-2002A patent/SK286694B6/sk not_active IP Right Cessation
- 2000-05-22 EA EA200201058A patent/EA005179B1/ru not_active IP Right Cessation
-
2001
- 2001-05-17 PE PE2001000439A patent/PE20011323A1/es not_active Application Discontinuation
- 2001-05-17 JO JO200172A patent/JO2310B1/en active
- 2001-05-18 EP EP01112230A patent/EP1157689B1/en not_active Revoked
- 2001-05-18 DK DK10166800.2T patent/DK2223682T3/da active
- 2001-05-18 DK DK01112230T patent/DK1157689T3/da active
- 2001-05-18 DE DE122009000035C patent/DE122009000035I1/de active Pending
- 2001-05-18 EP EP07004772A patent/EP1787639B1/en not_active Expired - Lifetime
- 2001-05-18 ES ES04011423T patent/ES2318217T3/es not_active Expired - Lifetime
- 2001-05-18 AT AT01112230T patent/ATE419832T1/de active
- 2001-05-18 ES ES10166800T patent/ES2380790T3/es not_active Expired - Lifetime
- 2001-05-18 DE DE60144304T patent/DE60144304D1/de not_active Expired - Lifetime
- 2001-05-18 DK DK07004772.5T patent/DK1787639T3/da active
- 2001-05-18 EP EP04011423A patent/EP1466594B1/en not_active Expired - Lifetime
- 2001-05-18 MY MYPI20060219A patent/MY143733A/en unknown
- 2001-05-18 PT PT01112230T patent/PT1157689E/pt unknown
- 2001-05-18 SI SI200131010T patent/SI2223682T1/sl unknown
- 2001-05-18 DE DE60136864T patent/DE60136864D1/de not_active Expired - Lifetime
- 2001-05-18 SI SI200130902T patent/SI1466594T1/sl unknown
- 2001-05-18 DK DK04011423T patent/DK1466594T3/da active
- 2001-05-18 MY MYPI20012370 patent/MY127145A/en unknown
- 2001-05-18 SI SI200130907T patent/SI1157689T1/sl unknown
- 2001-05-18 AT AT04011423T patent/ATE415945T1/de active
- 2001-05-18 DE DE60137282T patent/DE60137282D1/de not_active Expired - Lifetime
- 2001-05-18 AT AT07004772T patent/ATE502624T1/de active
- 2001-05-18 PT PT10166800T patent/PT2223682E/pt unknown
- 2001-05-18 SI SI200130992T patent/SI1787639T1/sl unknown
- 2001-05-18 PT PT07004772T patent/PT1787639E/pt unknown
- 2001-05-18 PT PT04011423T patent/PT1466594E/pt unknown
- 2001-05-18 AT AT10166800T patent/ATE541563T1/de active
- 2001-05-18 EP EP10166800A patent/EP2223682B1/en not_active Expired - Lifetime
- 2001-05-18 ES ES07004772T patent/ES2359991T3/es not_active Expired - Lifetime
- 2001-05-18 ES ES01112230T patent/ES2320194T3/es not_active Expired - Lifetime
- 2001-05-21 US US09/860,689 patent/US6716414B2/en not_active Expired - Lifetime
- 2001-05-21 AR ARP010102397A patent/AR029523A1/es not_active Application Discontinuation
- 2001-05-21 SA SA01220126A patent/SA01220126B1/ar unknown
- 2001-05-22 TN TNTNSN01074A patent/TNSN01074A1/fr unknown
- 2001-05-22 TW TW090112202A patent/TWI284047B/zh not_active IP Right Cessation
-
2002
- 2002-11-08 BG BG107256A patent/BG65883B1/bg unknown
- 2002-11-20 NO NO20025568A patent/NO342935B1/no not_active IP Right Cessation
- 2002-11-20 IL IL152955A patent/IL152955A/en not_active IP Right Cessation
-
2003
- 2003-08-14 US US10/640,005 patent/US7018618B2/en not_active Expired - Lifetime
-
2005
- 2005-05-22 ME MEP-321/08A patent/MEP32108A/xx unknown
- 2005-11-30 US US11/289,479 patent/US20060083693A1/en not_active Abandoned
-
2009
- 2009-02-27 CY CY20091100233T patent/CY1108833T1/el unknown
- 2009-04-03 CY CY20091100391T patent/CY1108968T1/el unknown
- 2009-07-03 CY CY2009009C patent/CY2009009I2/el unknown
- 2009-07-03 NL NL300393C patent/NL300393I2/nl unknown
-
2011
- 2011-06-20 CY CY20111100584T patent/CY1111570T1/el unknown
- 2011-09-20 BE BE2011C032C patent/BE2011C032I2/nl unknown
- 2011-09-20 DE DE201112100049 patent/DE122011100049I1/de active Pending
- 2011-09-20 LT LTPA2011011C patent/LTC1787639I2/lt unknown
- 2011-09-21 LU LU91875C patent/LU91875I2/fr unknown
- 2011-09-22 CY CY2011014C patent/CY2011014I1/el unknown
- 2011-09-23 FR FR11C0041C patent/FR11C0041I2/fr active Active
-
2012
- 2012-04-18 CY CY20121100369T patent/CY1113028T1/el unknown
-
2018
- 2018-07-13 HU HUS1800032C patent/HUS1800032I1/hu unknown
-
2019
- 2019-01-16 NO NO2019003C patent/NO2019003I1/no unknown
- 2019-07-11 NO NO2019030C patent/NO2019030I1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA73986C2 (uk) | АЕРОЗОЛЬНА КОМПОЗИЦІЯ, ЩО МІСТИТЬ <font face="Symbol">b</font>2-АДРЕНЕРГІЧНИЙ АГОНІСТ ТРИВАЛОЇ ДІЇ, ДОЗУЮЧИЙ ІНГАЛЯТОР ПІД ТИСКОМ ТА СПОСІБ ЙОГО ЗАПОВНЕННЯ | |
| DK3089735T3 (en) | STABLE PRESSURE AEROSOL SOLUTION COMPOSITION OF GLYCOPYRRONIUM BROMIDE AND FORMOTEROL COMBINATION | |
| BG62119B1 (bg) | Лекарствено средство | |
| AU2012358475B2 (en) | An inhalable medicament comprising tiotropium | |
| US20070256685A1 (en) | Aerosol Formulations Comprising Formoterol Fumarate Dihydrate | |
| EP1670443B1 (en) | Aerosol formulation comprising formoterol in suspension | |
| US20170020852A1 (en) | Inhalable Medicament Comprising Tiotropium | |
| JP5409594B2 (ja) | 加圧式定量吸入器のための安定な製薬学的溶液製剤 | |
| CA3152578A1 (en) | Stainles steel can for pressurised metered dose inhalers |